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P
ulmonary hypertension (PH) is a hemodynamic finding that may be caused by variable combinations of increased pulmonary blood flow, pulmonary venous hypertension (PVH), pulmonary vasoconstriction, or pulmonary vascular (PV) remodeling. Vascular remodeling results in luminal narrowing and an increase in resistance to blood flow. The vascular narrowing in PH may be caused by hypertrophy or proliferation of smooth muscle in the media of pulmonary arteries or diverse processes that result in thickening of the intima in pulmonary arteries or veins.
Idiopathic (group 1.1) pulmonary arterial hypertension (PAH) is known to be caused by an isolated pulmonary arteriopathy with sparing of pulmonary veins. The efficacy of PAH therapies was first established in this group. 1 Group 1 PAH (pulmonary veno-occlusive disease [PVOD] ) is characterized by preferential remodeling of pulmonary venous intima with secondary arterial changes. 2 In PVOD, there is a risk of pulmonary edema with and limited responsiveness to PAH therapies. 3, 4 The nature and severity of venous remodeling in other types of PH and the relationship between venous and arterial remodeling across the spectrum of PH severity are not well defined. 1, 5 Heart failure (HF) is a common cause of PH (group 2 PH) 6 and may be associated with preserved ejection fraction (HFpEF) or reduced EF (HFrEF). In HF, the severity of PH is associated with adverse outcomes irrespective of EF. [7] [8] [9] [10] Pulmonary vascular remodeling may contribute to the severity of PH in HF and support consideration of clinical trials of PAH therapies in HFpEF. 11 Previous investigators [12] [13] [14] [15] [16] [17] [18] [19] have reported pulmonary arterial and venous remodeling in left heart disease (predominately mitral stenosis and congenital lesions), but a systematic study of PV remodeling in typical HFpEF and HFrEF is lacking.
We hypothesized that the chronic PVH in HF may lead to preferential remodeling of pulmonary veins and that the severity of PH and the presence of right ventricular (RV) dysfunction in HF are associated with the severity of venous remodeling irrespective of EF. Further, because PH associated with left heart disease is reversible, we speculated that the character of the venous intimal remodeling in HF may differ from PVOD, a largely irreversible condition. 3 Finally, because the diffusing capacity for carbon monoxide (DLCO) is variably reduced in HF and nearly uniformly reduced in PVOD, we speculated that the severity of PV remodeling may be associated with reductions in DLCO.
Accordingly, we performed comprehensive quantitative histomorphometry with qualitative assessment of intimal character and morphology in pulmonary vessels in autopsy specimens from patients with an antemortem diagnosis of HF (HFpEF and HFrEF) and varying severities of PH. Findings were compared to those in autopsy or surgical specimens from normal controls and patients with primary PVOD. The severity of PH and the presence of RV dysfunction were defined by antemortem Doppler echocardiography and (when available) right heart catheterization (RHC). The DLCO was measured by antemortem pulmonary function tests (PFTs) when available.
METHODS
The data, analytic methods, and study materials will not be made available to other investigators. The study was approved by the Mayo Clinic Institutional Review Board and its Bio-Specimens Subcommittee. Only cases with consent for use of their specimens for research were included.
Selection of Subjects With HF-PH
Study subjects were identified from autopsy cases from the Mayo Clinic Tissue Registry from 1987 to 2015. Subjects with a clinical diagnosis of HF with a pulmonary artery systolic pressure ≥40 mm Hg and meeting the inclusion and exclusion criteria as outlined in the Methods and Figure I in the online-only Data Supplement were included. Patients with HF with other conditions recognized to cause PH were excluded, including those with significant lung disease based on clinical diagnosis, PFT findings, or pulmonary histological findings at autopsy.
Selection of Primary PVOD Cases
Primary PVOD subjects were identified from consecutive cases with histological diagnosis of PVOD or PVOD-like changes
Clinical Perspective
What Is New?
• In patients with heart failure (HF) with preserved ejection fraction or reduced ejection fraction and pulmonary hypertension, there is global pulmonary vascular remodeling with thickening of the media and intima in arteries and thickening of the intima in veins and small pulmonary vessels relative to normal control subjects.
• Venous and small vessel intimal thickening was more severe than arterial intimal thickening in HF, with a pattern similar to patients with pulmonary veno-occlusive disease.
• The severity of pulmonary hypertension correlated most strongly with venous and small vessel (rather than arterial) remodeling.
What Are the Clinical Implications?
• These findings add to our understanding of the pathobiology of HF-related pulmonary hypertension.
• Pulmonary venous remodeling in HF may predispose to worsening alveolar edema with pulmonary vasodilators, as in primary pulmonary veno-occlusive disease.
• Our findings suggest that there is an unmet need for effective treatments that target pulmonary venous remodeling in HF-pulmonary hypertension.
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from the Mayo Clinic Tissue Registry database and from 5 PVOD cases (1930 5 PVOD cases ( -1983 reported in a previously published study 20 and as outlined in the Methods and Figure 
Selection of Normal Controls
Twelve normal controls, with similar age and sex as the HF-PH group, without any heart or lung disease or any condition associated with PVOD or other forms of PH reported in medical records or identified at autopsy, were obtained from the Mayo Clinic Tissue Registry autopsy archives.
Demographics and Clinical and Cardiac Autopsy Characteristics
Clinical information was abstracted from the medical records. Echocardiographic, PFT, and RHC data extracted from the reports were provided by the respective Mayo Clinic clinical laboratories as outlined in the Methods in the online-only Data Supplement.
Histomorphometry
A detailed description of specimen preparation and analysis is provided in the Methods in the online-only Data Supplement. At least 2 blocks from different lung laterality and lobes were procured from each case ( Table I in the online-only Data Supplement), stained with hematoxylin and eosin and Verhoeff-van Gieson, and captured with whole-field digital microscopy ( Figure III in the online-only Data Supplement). Pulmonary arteries were distinguished from pulmonary veins based on both position and structure. When position and structure of a vessel did not definitively identify it as an artery/ arteriole or vein/venule (primarily small [<100 µm] vessels), the vessel was designated as an indeterminate vessel (IV) and analyzed separately. Histomorphometric measurements of vessels utilized rigorous criteria for analytic suitability. All vessels suitable for analysis were measured in each patient ( Figure III in the online-only Data Supplement). The percent medial thickness (%MT) (arteries) and percent intimal thickness (%IT) (arteries, veins, and IV) were calculated relative to external diameter (Methods and Figure IV in the online-only Data Supplement ) as previously described. 19, 21 For each vessel measured, intimal morphology was qualitatively categorized as eccentric, concentric, occlusion, or luminal webs/recanalization, and the character of intimal remodeling, irrespective of the cellularity, was qualitatively categorized as dense fibrosis, loose fibrosis, or intimal hyalinosis (Methods and Figure IV in the online-only Data Supplement). Veins with loosely fibrotic intimal remodeling and intimal hyalinosis were combined into 1 category for analysis.
Statistical Analysis
Data were summarized with frequencies and percentages for categorical variables and with medians and interquartile ranges for continuous data. When data were not available in all subjects, the number of subjects with data was reported. Data at the patient level were compared between groups with χ 2 tests or Fisher exact test for categorical data and with t tests or Wilcoxon rank-sum tests for continuous data as appropriate.
The %MT for all measured arteries and the %IT for all vessels (arteries, veins, and IV) were compared among patient groups (control, HF-PH, and PVOD), with random-intercept mixed-effects linear regression models to account for the multiple measurements per patient using a compound symmetry correlation structure. Each model also allowed for heterogeneous variance across the patient groups after graphically noting a difference in variance among PVOD, HF-PH, and normal patients at the vessel level. The normality of the conditional residuals from each model was assessed graphically. The mean and standard error within each group were estimated from these models.
The percentage of arteries, veins, and IVs that had different qualitative remodeling characteristics (eccentric or concentric, dense or loose fibrosis, etc) was calculated for each patient. The group data were summarized with medians and interquartile ranges of the percent vessels per patient, with the qualitative remodeling characteristic, and compared with pairwise Wilcoxon rank-sum tests.
To assess associations with patient-level measurements (pulmonary artery systolic pressure [PASP] , RHC, and PFT data), the %MT (arteries) and %IT (arteries, veins, or IV) were averaged for each patient, and these patient-level averages were used as predictors in linear regression models, alone and with other adjustment variables. The normality and homoscedasticity assumptions of the residuals for linear regression were assessed graphically. Pearson correlations (r) and the coefficient of determination from linear regression models (R 2 ) were reported. All analyses were performed using SAS version 9.4 (SAS Institute Inc), and figures were generated using R 22 or GraphPad Prism (version 5.00 for Windows, GraphPad Software, La Jolla, CA, www.graphpad.com). P values <0.05 were considered statistically significant, and no adjustment for multiple comparisons was made.
RESULTS

Cohort Demographics and Clinical Characteristics
The patients with HF-PH (n=108) were older and more likely to be female than patients with PVOD (n=17), but by design, age and sex were similar in patients with HF-PH and controls (n=12) ( Table 1 ). The patients with HF-PH were more obese and had or tended to have more cardiovascular risk factors, mild lung disease, and renal dysfunction than controls or patients with PVOD. A history of smoking was present in a similar percentage of patients with HF-PH, PVOD, and controls, but patients with HF-PH had or tended to have a higher prevalence of obstructive sleep apnea (OSA) than controls or patients with PVOD.
Among patients with echocardiography (HF-PH and PVOD), the median time between the echocardiogram with the highest PASP and death/surgery was 101 days in HF-PH and 39 days in PVOD ( Table 1) . The patients with HF-PH had lower PASP (median, 59 [interquartile range, 50-70] mm Hg) than patients with PVOD (median, 91 [interquartile range, 82-103] mm Hg). The patients with HF-PH were less likely to have RV enlargement (60%) or dysfunction (61%) than those with PVOD (100% had both). The EF was lower, whereas the E/e' ratio and prevalence of left atrial enlargement were higher in HF-PH than PVOD.
Among patients with HF-PH, those with HFpEF were older and less likely male, were more likely obese, and had a higher prevalence of hypertension and atrial fibrillation than patients with HFrEF (Table II in the onlineonly Data Supplement). The patients with HFpEF were less likely to have smoked but had a similar prevalence of lung disease, OSA, and renal dysfunction as patients with HFrEF. Left ventricular size was smaller, whereas left ventricular wall thicknesses and mass were greater in HFpEF, but the E/e' ratio and the prevalence of left atrial enlargement and RV enlargement and dysfunction were not significantly different in HFpEF and HFrEF. The PASP was numerically higher in HFpEF, but this difference was not statistically significant. At autopsy, heart weights were higher in HFrEF than HFpEF, but the percentage of predicted heart weight (accounting for age, sex, and body size 23 ) was similar in the 2 groups (Table III in 
PV Remodeling in HF-PH
The right upper and left lower lobes were the most frequently sampled lobes in all groups (Table I in the online-only Data Supplement). Overall, 14 747 vessels were analyzed. On average, ≈30 arteries, 50 veins, and 7 IV per patient were analyzed in each control and patient with HF-PH, and ≈50 arteries, 80 veins, and 54 IV were analyzed in each patient with PVOD. There were more analyzable vessels in PVOD because preparation of surgical and autopsy specimens purposefully maxi- Data are n (%), n/n with data (%), or median (IQR). BMI indicates body mass index; eGFR, estimated glomerular filtration rate; HF, heart failure; IQR, interquartile range; LA, left atrial; NA, not available or applicable; OSA, obstructive sleep apnea; PASP, pulmonary artery systolic pressure; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; and RV, right ventricle.
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mized small (peripheral) vessels owing to the clinical suspicion of PVOD. Within the lungs of individual patients, the %MT in arteries and the %IT in arteries, veins, and IV varied considerably in HF-PH and PVOD (Figure 1 ) but were more consistent in controls. Patients with HF-PH displayed higher %MT in arteries and greater %IT in arteries, veins, and IV compared with controls, but %MT in arteries and %IT in arteries, veins, and IV were all lower compared with PVOD (Table 2 and Figures 1 and 2) . The percentage of veins with arterialization was higher in HF-PH than controls or PVOD ( Table 2 ). The %MT in arteries and the %IT in arteries and veins tended to be more severe (P=0.07 for all) in HFpEF than HFrEF, and the %IT in IV was significantly higher in HFpEF than HFrEF (Table III in When present, the character of IT in arteries and IV was rarely that of loose fibrosis/hyalinosis irrespective of study group (Table 2 ). In contrast, in veins, the IT in HF-PH could be densely fibrotic or show loose fibrosis or hyalinosis (Figure 3 ). The frequency of loose fibrosis/ hyalinosis did not vary with HF type (Table III in the online-only Data Supplement). The venous intima in PVOD was consistently densely fibrotic (Table 2 and Figure 3 ) and only rarely (68 of 1488 veins) showed loose fibrosis/hyalinosis. The normal intima in control veins also sometimes displayed a loose fibrosis/hyalinosis character ( Table 2 and Figure 3 ). It is important to note that in veins from controls and patients with HF-PH, the severity of IT was greater in veins with loose fibrosis/hyalinosis compared with veins with dense fibrosis (Figure VI in the online-only Data Supplement), whereas in PVOD, the %IT was similar in veins irrespective of intimal character.
The arterial intima was seldom concentric, whereas the venous and IV intima were more often concentric irrespective of study group. Occluded or recanalized intima was not seen in HF-PH or controls but was present in a small number of PVOD vessels ( Table 2 ). 
Impact of Comorbidities on PV Remodeling
Because patients with significant lung disease were excluded from the HF-PH cohort, when present, the severity of lung disease was mild, and PASP and PV remodeling were similar in those patients with HF-PH with or without mild lung disease (Table VI in the online-only Data Supplement). Similarly, PASP and PV remodeling were similar in those patients with HF-PH with or without OSA (Table VI in the online-only Data Supplement). Although PASP was not significantly different in those patients with HF-PH with an estimated glomerular filtration rate above versus below the median value in HF-PH, venous and IV intimal remodeling were more severe in patients with worse renal function (Table VI in the online-only Data Supplement).
Relationship Between PV Remodeling and RV Function
Among patients with HF-PH, PASP was higher in those with (n=60) than without (n=38) RV dysfunction at echocardiography (64 [55-74] versus 52 [46-62] mm Hg, P=0.005). However, the severity of arterial, venous, and IV remodeling was not significantly different in those patients with or without RV dysfunction (P>0.23 for all). Data are shown as median (interquartile range) unless otherwise noted. HF indicates heart failure; %IT, percent intimal thickening; IV, indeterminate vessels; %MT, percent medial thickening; PH, pulmonary hypertension; and PVOD, pulmonary veno-occlusive disease.
*Means and P values estimated from mixed model to account for repeated measures within patients. Data summarized as mean (SEM) from these models.
†Equal to 0% for all observations (no variability).
In 29 patients, the RV dysfunction was characterized as mild, and in 30 patients, the RV dysfunction was characterized as moderate or severe. The severity of vascular remodeling in these 2 groups was not different than those without RV dysfunction (P>0.13 for all).
Findings in Patients With PH Characterized by RHC
A subgroup of patients with HF-PH (n=30; 16 with HFrEF and 14 with HFpEF) and nearly all patients with PVOD (n=16) had undergone RHC at some point (median of 22 days in HF-PH and 40 days in PVOD) before death/ surgery. Although patients with HF-PH undergoing RHC were younger than those who did not, the differences in clinical characteristics between HF-PH and PVOD in the RHC cohorts (Table VII in the online-only Data Supplement) were similar to that observed in all patients.
Right atrial and pulmonary artery wedge pressures were higher in patients with HF-PH than those with PVOD (Table VII in the online-only Data Supplement). The cardiac output tended to be higher in HF-PH than PVOD, but the cardiac index was similar. Pulmonary artery systolic, diastolic, and mean pressures were lower in patients with HF-PH than those with PVOD. . ED indicates external diameter; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and PVOD, pulmonary veno-occlusive disease.
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The transpulmonary gradient (TPG) was lower in HF-PH than PVOD (16 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] versus 45 [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] mm Hg). Pulmonary vascular resistance (PVR) was also lower in HF-PH than PVOD. In the RHC subgroup, the degree of PV remodeling was less severe in HF-PH than in PVOD ( Figure 5 and Table VII in the online-only Data Supplement). Arterial medial and intimal, and venous and IV intimal remodeling correlated with the severity of PH as measured by TPG (Figure 6 ), with the numerically strongest relationships noted for venous and IV IT. These associations persisted after adjustment for lung disease, OSA, and renal function (Table VIII in the online-only Data Supplement). Similar relationships were present with PVR ( Figure VII in the online-only Data Supplement). The diastolic pressure gradient calculated from the reported pulmonary artery wedge and diastolic pressures was lower in HF-PH (6 [2-9] mm Hg; n=22) than PVOD (28 [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] 
PV Remodeling and Lung Function
A subgroup of patients with HF-PH (n=43) and nearly all patients with PVOD (n=14) had undergone PFT at some point before surgery/death (median, 326 days in HF-PH and 75 days in PVOD). The differences in clinical characteristics between HF-PH and PVOD in the PFT cohort (Table IX in the online-only Data Supplement) were similar to those observed in all patients. On average, patients with HF displayed a mild mixed obstructive/ restrictive pattern on spirometry, whereas spirometry was normal in PVOD (Table IX in the online-only Data Supplement).
Pulmonary arterial vasoconstriction or remodeling can reduce capillary blood volume and, thus, DLCO. Increases in pulmonary venous pressure because of left heart disease or remodeling of the small pulmo- is not shown on this scale. HFpEF indicates heart failure with preserved ejection fraction; HF-PH, heart failure-pulmonary hypertension; HFrEF, heart failure with reduced ejection fraction; %IT, percent intimal thickening; IV, indeterminate vessels; %MT, percent medial thickening; PASP, pulmonary artery systolic pressure; and PVOD, pulmonary veno-occlusive disease.
nary veins can lead to interstitial edema and restrictive physiology, with reduction in alveolar volume and alveolar-capillary membrane conductance, reducing DLCO. On average, percent predicted total lung capacity, a surrogate for alveolar volume, was similar in patients with HF-PH and PVOD, but the percentage that predicted DLCO was higher in HF-PH (median, 55%) than PVOD (median, 37%; Table IX in 
DISCUSSION
In this study of PV remodeling in HF with reduced or preserved EF and a spectrum of PH severity, there was significant variability in the extent of arterial, venous, and IV remodeling within each patient with HF-PH, underscoring the potential for sampling bias if small numbers of vessels are analyzed. Relative to controls, patients with HF-PH displayed global (arteries, veins, and IV) PV remodeling, including prominent IT in veins and IV. This pattern was similar to, but less severe than, that observed in the patients with PVOD who, on average, also had more severe PH. The character of venous intimal remodeling was unique in HF-PH compared with PVOD, with obstruction more often because of loose fibrosis and hyalinosis. In HF-PH and PVOD, the sever- . ED indicates external diameter; HFpEF, heart failure with preserved ejection fraction; HF-PH, heart failure-pulmonary hypertension; HFrEF, heart failure with reduced ejection fraction; IV, indeterminate vessels; PVOD, pulmonary veno-occlusive disease; and TPG, transpulmonary gradient.
ity of PH was correlated with arterial, venous, and IV remodeling but most strongly/independently with venous and IV IT. Although RV dysfunction was common in HF-PH and associated with higher PASP, the severity of PV remodeling was not greater in patients with versus without RV dysfunction. The DLCO was variably but substantially reduced in HF-PH and markedly reduced in PVOD. Adjusting for differences in lung volumes, both arterial and small IV IT were associated with reductions in DLCO.
As emphasized in the proceedings from the pathology and pathobiology working group of the Fifth World Symposium on Pulmonary Hypertension, 5 the histological alterations of the pulmonary veins are understudied in PH of all etiologies, and there is a need to better understand the relationships between arterial and venous remodeling across the spectrum of mild to severe PH. The importance of pulmonary venous remodeling in PH is underscored by its well-recognized, primary role in causing PH in PVOD 2 and its implications for prognosis and therapy. Of all forms of PAH, PVOD has the worst prognosis. 3 In PVOD, the presence of extensive venous remodeling can result in increases in the transcapillary hydrostatic pressure gradient and, consequently, pulmonary edema with increases in pulmonary arterial blood flow in response to pulmonary artery-specific vasodilators. 4 Although the use of PAH therapies in recognized PVOD is not well studied, they are less effective in PVOD even if tolerated. 3, 4 Other types of PAH are believed to be associated with variable combinations of arterial and venous remodeling, but precise documentation of venous remodeling across the spectrum of PAH etiologies and severities is lacking, 5 in part, because of the challenges of pulmonary venous histomorphometry. There is no specific stain to discriminate between small arteries and veins, and histological techniques to accurately identify veins are laborious and require careful attention to vessel morphology and location.
Previous studies [12] [13] [14] [15] [16] [17] [18] [19] have documented pulmonary arterial and venous remodeling in left heart disease (primarily mitral stenosis and congenital heart disease), but most were old and largely qualitative studies without systematic morphometric analysis, assessment of the character of intimal remodeling, or rigorous statistical analysis. Most included small numbers of patients, ex- amined small numbers of vessels per patient, and did not examine the relationship between arterial and venous remodeling across a range of PH severity or according to HF type and did not relate the relationship between remodeling and pulmonary hemodynamics. Delgado et al 24 measured %MT in a cohort (n=17) of patients with HF who died shortly after heart transplantation and found higher %MT in those with elevated PVR/TPG.
More recently, Hunt et al 15 performed arterial and venous histomorphometric analysis in 19 controls (failed organ donors, transplantation specimens) and 22 patients with HFrEF with relatively advanced PH (TPG of 18.6 mm Hg, PVR of 4.7 Wood units), who underwent wedge lung biopsy at the time of left ventricular assist device placement. A median of 6 arteries per patient were analyzed, but the number of veins analyzed in each patient was not reported. Average pulmonary arterial and venous MT and IT were all increased in HFrEF relative to controls, consistent with our findings. However, the relationships between arterial and venous remodeling, the nature of intimal remodeling, and the relationship between pulmonary hemodynamics and PV remodeling were not described. It is important to note that 3 patients had a repeat lung biopsy after a prolonged period of cardiac unloading, and 1 of the 3 had a dramatic reduction in mean pulmonary arterial pressure associated with marked reductions in arterial and venous MT and IT.
Although much emphasis has been placed on pulmonary arterial MT and IT and their relationship to PH severity in different forms of PAH, here the venous and small IV remodeling appeared more strongly related to PH severity in HF, with pulmonary arterial intimal remodeling having the weakest correlation with PH severity. Thickening of the arterial media correlated well with the severity of venous and IV (but not arterial) IT. These findings suggest that arterial MT in HF reflects a hypertrophic response to the downstream obstruction provided by both venous and IV remodeling, as well as the chronic PVH related to underlying left heart disease.
The venous IT in patients with HF-PH displayed a loosely fibrotic or hyaline-type appearance in a subset of veins, coexisting with veins showing densely fibrotic venous IT. Venous IT because of loose fibrosis/hyalinosis was rarely seen in patients with PVOD. Intimal hyalinosis has not been systematically studied but has been attributed to the deposition of hyaline connective tissue, including extracellular matrix, which is also termed edematous intima by some pathologists. 17, 18, 25 In patients with HF-PH, a median of 25% of veins showed this appearance, but there was significant variability. Indeed, in 25% of patients with HFpEF, >50% of veins showed this appearance. We speculate that such remodeling may resolve more readily than dense fibrosis and contribute to the reversibility of PH with cardiac unloading in HF. Although the severity of PH as assessed by PASP and TPG correlated with the extent of PV remodeling, the relative contributions of remodeling and vasoconstriction to PH severity cannot be ascertained from the current study.
Multiple mechanisms may contribute to PV remodeling in HF. 26 The PVH in HF may cause venous endothelial disruption because of edema or mechanical distension of the pulmonary veins and result in activation of growth factors. Inflammation from venous mechanical stress and the proinflammatory milieu in HF may also contribute. In situ pulmonary venous thrombosis may play a role. 17 The effect of HF-related neurohumoral activation on PV remodeling in HF is uncertain, although neurohumoral activation is believed to play an important role in contributing to vascular remodeling in other forms of PAH. 27 The proceedings from the working group on PH in left heart disease at the 5th World Symposium on Pulmonary Hypertension advance a paradigm wherein the mechanism of PH in HF progresses from the purely passive effect of PVH to pulmonary arterial vasoconstriction and finally to PV remodeling with subsequent development of RV dysfunction. 11 In the present study, we observed global PV remodeling and, particularly, venous and small IV remodeling in HF across a broad spectrum of PH severities. We also found no difference in the severity of pulmonary vascular remodeling among patients with HF with versus without RV dysfunction. These findings suggest that PV remodeling is likely an early and progressive process and that RV dysfunction may not necessarily be directly related to the severity of pulmonary vascular remodeling. In contrast to most other forms of PAH, patients with HF often have intrinsic RV myocardial dysfunction because of ischemic heart disease or cardiomyopathic processes in HFrEF and because of ischemic heart disease, RV pacing, atrial fibrillation, or global cardiac microvascular inflammation in HFpEF. 9, [28] [29] [30] Thus, RV dysfunction may be influenced by but not as directly linked to the severity of remodeling in HF, compared with otherwise healthy persons who develop other forms of PAH in the absence of intrinsic myocardial disease.
On average, patients with HF-PH showed mild mixed obstructive/restrictive pulmonary dysfunction, with clinically relevant reductions in the DLCO, whereas patients with PVOD had normal spirometry but more severe reduction in DLCO, consistent with previous studies. 2, [31] [32] [33] [34] In HF and PVOD, reductions in DLCO have been attributed to the combined effects of PV remodeling with reduction in pulmonary capillary blood volume and impaired alveolar-capillary conductance because of interstitial edema. 2, 32, 34 In a study of alveolar and pulmonary arterial histomorphometry in 20 patients with mitral stenosis, Jordan et al 35 concluded that reductions in DLCO correlated more with pulmonary arterial than alveolar structural changes. In our study, adjusting for lung volumes (which correlated strongly with DLCO), IT in arteries and small IV remained associated with re-
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ductions in DLCO, providing a structural basis for the observed impairments in lung gas transfer in HF-PH. Although lung disease, OSA, and renal dysfunction are recognized contributors to PH, neither OSA nor the mild lung disease present in some patients with HF-PH was associated with differential PV remodeling. It is interesting to note that worse renal function was associated with more venous and IV intimal remodeling. Whether this is related to more chronic or severe PVH with renal dysfunction or other factors such as inflammation or humoral activation with worsening renal function is not clear.
Our findings have several clinical implications. The current findings may provide insight into the poorer tolerance and lack of response to different PAH therapies in HF-PH that has been noted in some [36] [37] [38] [39] but not all [40] [41] [42] studies. Although patients with HF are known to have functional PVOD because of their left heart disease, the pulmonary venous remodeling in HF may also predispose to worsening alveolar edema with pulmonary vasodilators, as in primary PVOD. Whether the antiproliferative effects of PAH therapies are similar in pulmonary arteries and veins is unclear, but our findings suggest that there is an unmet need for effective treatments that target pulmonary venous remodeling in HF-PH. The frequent presence of loose fibrosis or hyalinosis in pulmonary veins may explain the rapid reversibility of even severe PH in HF with effective decongestion, although this remains highly speculative.
Parenthetically, for clinical investigators and anatomic pathologists studying PVOD, the current study confirms and extends previous studies emphasizing caution in diagnosing PVOD in patients with left heart disease and, particularly, the importance of excluding HFpEF as a cause of PVOD-like changes. 
Strengths and Limitations
The strengths of the current study include rigorous case selection; comprehensive histomorphometry of all pulmonary vessels in a relatively large number of patients with HFpEF and HFrEF; pertinent comparison groups; study of a spectrum of PH severity in HF-PH; correlation of remodeling with pulmonary hemodynamics, RV function, and lung function; and rigorous analytic techniques. Limitations include the lack of invasive assessment of pulmonary hemodynamics and PFT in all patients and the lack of these measures immediately before tissue ascertainment. We used semiquantitative assessment of RV function. However, our previous study in a large HFpEF cohort indicated that semiquantitative assessment of RV function was strongly related to adverse outcome. 9 Because nonmuscularized arterioles cannot be reliably distinguished from venules without pretagging, we are unable to specifically assess nonmuscularized arteriolar remodeling. Although sections from each lobe were obtained in a random fashion, we cannot rule out biased sampling. This study is largely descriptive but lays the foundation for future studies investigating the mechanisms of global PV remodeling in HF.
CONCLUSIONS
Irrespective of EF, in patients with HF and PH, remodeling of the pulmonary arteries, veins, and small IV occurs. The IT in veins and IV is prominent in HF and more severe than in arteries, a pattern similar to but less severe than that observed in patients with PVOD and more severe PH. The severity of PH correlates most strongly/independently with venous and IV IT rather than arterial changes. The presence of RV dysfunction was associated with moderately higher PASP but not significantly more severe PV remodeling, suggesting that intrinsic myocardial processes, PVH, and pulmonary vasoconstriction contribute to RV dysfunction in HF-PH. Pulmonary vascular remodeling is associated with reductions in DLCO. These findings add to our understanding of the pathobiology of HF-related PH.
